Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
31
×
san francisco
31
×
san francisco blog main
san francisco top stories
life sciences
biotech
national top stories
startups
boston blog main
boston top stories
deals
new york blog main
clinical trials
fda
software
new york top stories
san diego blog main
texas blog main
texas top stories
drugs
funding
san diego top stories
venture capital
innovation
investing
medical device
raleigh-durham blog main
seattle blog main
seattle top stories
vc
cancer
detroit blog main
detroit top stories
ipo
medical devices
texas
wisconsin blog main
wisconsin top stories
alphabet
austin
What
drug
medical
tech
therapy
based
company
startup
therapeutics
available
big
cancer
deal
expand
innovation
ipo
latest
let’s
medicine
million
news
proteins
texas
tx
biologics
biotech
catch
close
companies
data
drugs
firm
gene
help
humans
lands
life
make
medicines
software
tests
Language
unset
Current search:
" san francisco "
×
" national blog main "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com
5 years ago
Chevron Tech, Medical Informatics, ActivTrak, Linear & More TX Tech
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Auris Health Lands $220M to Expand Sales of Lung Testing Medical Robot
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
CPRIT Grants, TMC & Baird, Shipt & Drive.ai Expand, & More TX Tech
@xconomy.com
5 years ago
Exits in Austin, Pitch NASA, Diversity in Energy, & More TX Tech
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Verana Health Lands $30M Financing Led By GV, Adds Miki Kapoor as CEO
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com
5 years ago
Quest Analytics Buys Healthcare Compliance Software Firm BetterDoctor
@xconomy.com
6 years ago
Fictiv Raises $15M To Connect Tech Innovators & Parts Manufacturers
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed